Biolife Solutions, Inc. · NASDAQ:BLFS

Biolife Solutions — Merger or Acquisition (July 2026)

9 slides from Biolife Solutions's merger presentation, Jul 22, 2026

  1. Slide 1: Town Hall Meeting July 22, 2026

    Town Hall Meeting July 22, 2026

  2. Slide 2: Agenda

    2 o Who, what and why? o Potential benefits to stakeholders o What we know and don’t know o Next Steps o Q&A Agenda

  3. Slide 3: What, who and why?

    3 o BioLife (“BLFS”) has entered into a definitive agreement to be acquired by Repligen (“RGEN”) o $31 per share, 36% cash ($11.25/BLFS share) and 64% stock ($19.75/BLFS share) o Fixed Share Exchange Rate = .1442 shares of RGEN per BLFS share o $1.5 billion enterprise value or ~13x FY26 high end of

  4. Slide 4: Potential Benefits to Stakeholders

    4 o Team Members o Become a key part of a larger (2,200 FTE’s), more diversified, fast-growing company o Opportunities for professional growth in a larger company that can’t be matched as BLFS sits today o Seasoned management team focused on innovation and customers, with a culture of transparency o

  5. Slide 5: What we know and don't know

    5 o Things we know o RGEN intends to operate BLFS as an independent ”Business Unit” o No organizational changes between now and close, estimated in 3 to 4 months o No changes in base salary compensation or benefits for the first year of RGEN ownership o All unvested RSU’s will be vested at the time

  6. Slide 6: Next Steps

    6 o 3-4 months to close (anticipated before Thanksgiving at latest) o Leadership will work through HSR, SEC, and shareholder vote gating items o Business as usual in terms of operating the company; nothing changes The key is to continue to push forward on all fronts of the business as we have been.

  7. Slide 7: Cautionary Statement Regarding Forward-Looking Statements

    7 | Industry-Leading Solutions for Cell-Based Therapies © Copyright 2026 BioLife Solutions® Cautionary Statement Regarding Forward-Looking Statements Statements included in this communication, which are not historical in nature or do not relate to current facts, are intended to be, and are hereby id

  8. Slide 8: Additional Information and Where to Find It; Participants in the Solicitation

    8 | Industry-Leading Solutions for Cell-Based Therapies © Copyright 2026 BioLife Solutions® Additional Information and Where to Find It; Participants in the Solicitation; No Offer or Solicitation In connection with the Mergers, Repligen will file with the SEC a registration statement on Form S-4 (th

  9. Slide 9: Q&A

    9 Q&A Confidential ©2025. BioLife Solutions® All Rights Reserved.

BioLife Solutions — Merger or Acquisition (July 2026) on 6ix